Search

Your search keyword '"Geiran, Odd"' showing total 400 results
Start Over Author "Geiran, Odd"
400 results on '"Geiran, Odd"'

2. Jan Ludvig Svennevig

Author

Fiane, Arnt, primary, Fosse, Erik, primary, Geiran, Odd, primary, Karlsen, Harald, primary, Lindberg, Harald, primary, Larsen, Johan Pillgram, primary, and Vaage, Jarle, primary

Published
2023
Full Text
View/download PDF

7. Kolbjørn Forfang

Author

Edvardsen, Thor, primary, Aaberge, Lars, primary, Geiran, Odd, primary, Simonsen, Svein, primary, Kjekshus, John, primary, Platou, Eivind, primary, and Smiseth, Otto A., primary

Published
2022
Full Text
View/download PDF

9. Halfdan Ihlen

Author

Edvardsen, Thor, primary, Skulstad, Helge, primary, Smiseth, Otto A., primary, Fosse, Erik, primary, Simonsen, Svein, primary, and Geiran, Odd, primary

Published
2022
Full Text
View/download PDF

24. Hans Anton Rostad

Author

Fiane, Arnt E., primary, Geiran, Odd R., primary, Lindberg, Harald L., primary, Naalsund, Anne, primary, and Svennevig, Jan L., primary

Published
2020
Full Text
View/download PDF

26. Marfan syndrome: Evolving organ manifestations—A 10‐year follow‐up study

Author

Vanem, Thy Thy, primary, Böker, Tordis, additional, Sandvik, Gunhild F., additional, Kirkhus, Eva, additional, Smith, Hans‐Jørgen, additional, Andersen, Kai, additional, Drolsum, Liv, additional, Lundby, Rigmor, additional, Røe, Cecilie, additional, Krohg‐Sørensen, Kirsten, additional, Geiran, Odd R., additional, Paus, Benedicte, additional, and Rand‐Hendriksen, Svend, additional

Published
2019
Full Text
View/download PDF

33. Low Molecular Mass Myocardial Hyaluronan in Human Hypertrophic Cardiomyopathy

Author

Lorén, Christina, Dahl, Christen P., Do, Lan, Almaas, Vibeke M., Geiran, Odd R., Mörner, Stellan, Hellman, Urban, Lorén, Christina, Dahl, Christen P., Do, Lan, Almaas, Vibeke M., Geiran, Odd R., Mörner, Stellan, and Hellman, Urban

Abstract

During the development of hypertrophic cardiomyopathy, the heart returns to fetal energy metabolism where cells utilize more glucose instead of fatty acids as a source of energy. Metabolism of glucose can increase synthesis of the extracellular glycosaminoglycan hyaluronan, which has been shown to be involved in the development of cardiac hypertrophy and fibrosis. The aim of this study was to investigate hyaluronan metabolism in cardiac tissue from patients with hypertrophic cardiomyopathy in relation to cardiac growth. NMR and qRT-PCR analysis of human cardiac tissue from hypertrophic cardiomyopathy patients and healthy control hearts showed dysregulated glucose and hyaluronan metabolism in the patients. Gas phase electrophoresis revealed a higher amount of low molecular mass hyaluronan and larger cardiomyocytes in cardiac tissue from patients with hypertrophic cardiomyopathy. Histochemistry showed high concentrations of hyaluronan around individual cardiomyocytes in hearts from hypertrophic cardiomyopathy patients. Experimentally, we could also observe accumulation of low molecular mass hyaluronan in cardiac hypertrophy in a rat model. In conclusion, the development of hypertrophic cardiomyopathy with increased glucose metabolism affected both hyaluronan molecular mass and amount. The process of regulating cardiomyocyte size seems to involve fragmentation of hyaluronan.

Published
2019
Full Text
View/download PDF

38. Hospital costs fell as numbers of LVADs were increasing: experiences from Oslo University Hospital

Author

Mishra Vinod, Fiane Arnt E, Geiran Odd, Sørensen Gro, Khushi Ishtiaq, and Hagen Terje P

Subjects
Innovative technology, Left ventricle assist device, Hospital cost, DRG reimbursement, Cost analysis, Surgery, RD1-811, Anesthesiology, RD78.3-87.3
Abstract

Abstract Background The current study was undertaken to examine total hospital costs per patient of a consecutive implantation series of two 3rd generation Left Ventricle Assist Devices (LVAD). Further we analyzed if increased clinical experience would reduce total hospital costs and the gap between costs and the diagnosis related grouped (DRG)-reimbursement. Method Cost data of 20 LVAD implantations (VentrAssist™) from 2005-2009 (period 1) were analyzed together with costs from nine patients using another LVAD (HeartWare™) from 2009-June 2011 (period 2). For each patient, total costs were calculated for three phases - the pre-LVAD implantation phase, the LVAD implantation phase and the post LVAD implant phase. Patient specific costs were obtained prospectively from patient records and included personnel resources, medication, blood products, blood chemistry and microbiology, imaging and procedure costs including operating room costs. Overhead costs were registered retrospectively and allocated to the specific patient by predefined allocation keys. Finally, patient specific costs and overhead costs were aggregated into total hospital costs for each patient. All costs were calculated in 2011-prices. We used regression analyses to analyze cost variations over time and between the different devices. Results The average total hospital cost per patient for the pre-LVAD, LVAD and post-LVAD for period 1 was $ 585, 513 (range 132, 640- 1 247, 299), and the corresponding DRG- reimbursement (2009) was $ 143, 192 . The mean LOS was 54 days (range 12- 127). For period 2 the total hospital cost per patient was $ 413, 185 (range 314, 540- 622, 664) and the corresponding DRG- reimbursement (2010) was $ 136, 963. The mean LOS was 49 days (range 31- 93). The estimates from the regression analysis showed that the total hospital costs, excluding device costs, per patient were falling as the number of treated patients increased. The estimate from the trend variable was -14, 096 US$ (CI -3, 842 to -24, 349, p Conclusion There were significant reductions in total hospital costs per patient as the numbers of patients were increasing. This can possibly be explained by a learning effect including better logistics, selection and management of patients.

Published
2012
Full Text
View/download PDF

40. Effect of Donor Age on Outcome of Lung Transplantation Stratified by Recipient Diagnosis: A Nordic Multicenter Study

Author

Auråen, Henrik, primary, Durheim, Michael Thomas, additional, Dellgren, Göran, additional, Hämmäinen, Pekka, additional, Larsson, Hillevi, additional, Geiran, Odd, additional, Schultz, Hans Henrik Lawaetz, additional, Leuckfeld, Inga, additional, Iversen, Martin, additional, Fiane, Arnt, additional, and Holm, Are Martin, additional

Published
2019
Full Text
View/download PDF

46. Marfan syndrome: Evolving organ manifestations—A 10‐year follow‐up study.

Author

Vanem, Thy Thy, Böker, Tordis, Sandvik, Gunhild F., Kirkhus, Eva, Smith, Hans‐Jørgen, Andersen, Kai, Drolsum, Liv, Lundby, Rigmor, Røe, Cecilie, Krohg‐Sørensen, Kirsten, Geiran, Odd R., Paus, Benedicte, and Rand‐Hendriksen, Svend

Abstract

The age‐dependent penetrance of organ manifestations in Marfan syndrome (MFS) is not known. The aims of this follow‐up study were to explore how clinical features change over a 10‐year period in the same Norwegian MFS cohort. In 2003–2004, we investigated 105 adults for all manifestations in the 1996 Ghent nosology. Ten years later, we performed follow‐up investigations of the survivors (n = 48) who consented. Forty‐six fulfilled the revised Ghent criteria. Median age: females 51 years, range 32–80 years; males 45 years, range 30–67 years. New aortic root dilatation was detected in patients up to 70 years. Ascending aortic pathology was diagnosed in 93 versus 72% at baseline. Sixty‐five percent had undergone aortic surgery compared to 39% at baseline. Pulmonary trunk mean diameter had increased significantly compared to baseline. From inclusion to follow‐up, two patients (three eyes) developed ectopia lentis, four developed dural ectasia, four developed scoliosis, three developed incisional or recurrent herniae, and 14 developed hindfoot deformity. No changes were found regarding protrusio acetabuli, spontaneous pneumothorax, or striae atrophicae. The study confirms that knowledge of incidence and progression of organ manifestations throughout life is important for diagnosis, treatment, and follow‐up of patients with verified or suspected MFS. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results